Stay updated with breaking news from Mark Rothera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Silence Therapeutics is mum no more on its short interfering RNA therapy, which has been found to significantly reduce levels of an independent risk factor for cardiovascular disease.
Investegate announcements from Silence Therapeutics, New Key Shareholder
IN BRIEF: Frazier Life picks up 3% interest in Silence Therapeutics | Financial News
Polycythaemia vera, a rare form of blood cancer. will be the third indication for SLN124
Investegate announcements from Silence Therapeutics, Silence Provides Pipeline Updates at 2021 R&D Day